FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com


Join the forum, it's quick and easy

FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com
FINANCIAL CHRONICLE™
Would you like to react to this message? Create an account in a few clicks or log in to continue.
FINANCIAL CHRONICLE™

Encyclopedia of Latest news, reviews, discussions and analysis of stock market and investment opportunities in Sri Lanka

Click Link to get instant AI answers to all business queries.
Click Link to find latest Economic Outlook of Sri Lanka
Click Link to view latest Research and Analysis of the key Sectors and Industries of Sri Lanka
Worried about Paying Taxes? Click Link to find answers to all your Tax related matters
Do you have a legal issues? Find instant answers to all Sri Lanka Legal queries. Click Link
Latest images

Latest topics

» PEOPLE'S INSURANCE PLC (PINS.N0000)
by ErangaDS Today at 10:24 am

» UNION ASSURANCE PLC (UAL.N0000)
by ErangaDS Today at 10:22 am

» ‘Port City Colombo makes progress in attracting key investments’
by samaritan Yesterday at 9:26 am

» Mahaweli Reach Hotels (MRH.N)
by SL-INVESTOR Wed Apr 24, 2024 11:25 pm

» THE KANDY HOTELS COMPANY (1983) PLC (KHC.N0000)
by SL-INVESTOR Wed Apr 24, 2024 11:23 pm

» ACCESS ENGINEERING PLC (AEL) Will pass IPO Price of Rs 25 ?????
by ddrperera Wed Apr 24, 2024 9:09 pm

» LANKA CREDIT AND BUSINESS FINANCE PLC (LCBF.N0000)
by Beyondsenses Wed Apr 24, 2024 10:40 am

» FIRST CAPITAL HOLDINGS PLC (CFVF.N0000)
by Beyondsenses Wed Apr 24, 2024 10:38 am

» LOLC FINANCE PLC (LOFC.N0000)
by Beyondsenses Wed Apr 24, 2024 10:20 am

» SRI LANKA TELECOM PLC (SLTL.N0000)
by sureshot Wed Apr 24, 2024 8:37 am

» COCR IN TROUBLE?
by D.G.Dayaratne Tue Apr 23, 2024 7:59 pm

» Sri Lanka confident of speedy debt resolution as positive economic reforms echoes at IMF/WB meetings
by samaritan Mon Apr 22, 2024 9:28 am

» TAFL is the most undervalued & highly potential counter in the Poultry Sector
by LAMDA Mon Apr 22, 2024 12:58 am

» Construction Sector Boom with Purchasing manager's indices
by rukshan1234 Thu Apr 18, 2024 11:24 pm

» Asha Securities and Asia Securities Target AEL (Access Enginnering PLC )
by Anushka Perz Wed Apr 17, 2024 10:30 pm

» Sri Lanka: China EXIM Bank Debt Moratorium to End in April 2024
by DeepFreakingValue Tue Apr 16, 2024 11:22 pm

» Uncertainty over impending elections could risk Lanka’s economic recovery: ADB
by God Father Tue Apr 16, 2024 2:47 pm

» Sri Lanka's Debt Restructuring Hits Roadblock with Bondholders
by God Father Tue Apr 16, 2024 2:42 pm

» BROWN'S INVESTMENTS SHOULD CONSIDER BUYING BITCOIN
by ADVENTUS Mon Apr 15, 2024 12:48 pm

» Bank run leading the way in 2024
by bkasun Sun Apr 14, 2024 3:21 pm

» ASPI: Undoing GR/Covid19!
by DeepFreakingValue Thu Apr 11, 2024 10:25 am

» Learn CSE Rules and Regulations with the help of AI Assistant
by ChatGPT Tue Apr 09, 2024 7:47 am

» Top AI tools in Sri Lanka
by ChatGPT Tue Apr 09, 2024 7:21 am

» HDFC- Best ever profit reported in 2023
by ApolloCSE Mon Apr 08, 2024 12:43 pm

» WAPO 200% UP
by LAMDA Sun Apr 07, 2024 10:41 pm

LISTED COMPANIES

Submit Post
ශ්‍රී ලංකා මූල්‍ය වංශකථාව - සිංහල
Submit Post


CONATCT US


Send your suggestions and comments

* - required fields

Read FINANCIAL CHRONICLE™ Disclaimer



EXPERT CHRONICLE™

ECONOMIC CHRONICLE

GROSS DOMESTIC PRODUCT (GDP)



CHRONICLE™ YouTube

Disclaimer
FINANCIAL CHRONICLE™ Disclaimer

The information contained in this FINANCIAL CHRONICLE™ have been submitted by third parties directly without any verification by us. The information available in this forum is not researched or purported to be complete description of the subject matter referred to herein. We do not under any circumstances whatsoever guarantee the accuracy and completeness information contained herein. FINANCIAL CHRONICLE™ its blogs, forums, domains, subdomains and/or its affiliates and/or its web masters, administrators or moderators shall not in any way be responsible or liable for loss or damage which any person or party may sustain or incur by relying on the contents of this report and acting directly or indirectly in any manner whatsoever. Trading or investing in stocks & commodities is a high risk activity. Any action you choose to take in the markets is totally your own responsibility, FINANCIAL CHRONICLE™ blogs, forums, domains, subdomains and/or its affiliates and/or its web masters, administrators or moderators shall not be liable for any, direct or indirect, consequential or incidental damages or loss arising out of the use of this information. The information on this website is neither an offer to sell nor solicitation to buy any of the securities mentioned herein. The writers may or may not be trading in the securities mentioned.

Further the writers and users shall not induce or attempt to induce another person to trade in securities using this platform (a) by making or publishing any statement or by making any forecast that he knows to be misleading, false or deceptive; (b) by any dishonest concealment of material facts; (c) by the reckless making or publishing, dishonestly or otherwise of any statement or forecast that is misleading, false or deceptive; or (d) by recording or storing in, or by means of, any mechanical, electronic or other device, information that he knows to be false or misleading in a material particular. Any action writers and users take in respect of (a),(b),(c) and (d) above shall be their own responsibility, FINANCIAL CHRONICLE™ its blogs, forums, domains, subdomains and/or its affiliates and/or its web masters, administrators or moderators shall not be liable for any, direct or indirect, consequential or incidental violation of securities laws of any country, damages or loss arising out of the use of this information.


AI Live Chat

You are not connected. Please login or register

Cancer drug success cuts short clinical trial

Go down  Message [Page 1 of 1]

mission


Manager - Equity Analytics
Manager - Equity Analytics

Advanced prostate cancer drug improved survival

Mon 26 Sep, 2011 12:00 am BST

A prostate cancer drug trial has been stopped early, because the treatment was found to be so effective.

Doctors at the Royal Marsden Hospital cut short the phase III clinical trial of the drug - Radium 233 chloride - in patients with advanced prostate cancer, after they found that it significantly improved overall patient survival.

"It would have been unethical not to offer the active treatment to those taking placebo," Dr Chris Parker, a clinical oncologist, told the European Multidisciplinary Cancer Congress in Stockholm.

The drug, also known as Alpharadin - is a type of alpha-pharmaceutical which works by delivering minute quantities of damaging alpha radiation to secondary cancer cells in the bone.

The researchers decided to test Alpharadin in prostate cancer patients, as the disease spreads to the bone in nine out of ten men with the advanced form of the disease.

Radium also sticks to bone, the researchers said, especially new bone that is being made, which makes it 'highly effective' at delivering radiation to target cancer cells.

"It takes only a single alpha particle to kill a cell," said Dr Parker explained, "and collateral damage is minimised because the particles have such a tiny range - a few millionths of a metre (micrometres).

"So we can be sure that the damage is being done where it should be, to the metastasis, and very limited elsewhere."

The study involved 922 men with advanced prostate cancer. In all cases, the cancer had also spread to the patients' bones.

The patients received either standard treatment or Alpharadin plus standard treatment.

The study found that patients taking standard treatment plus Alpharadin had a 30 per cent lower rate of death compared to patients receiving standard treatment and a placebo (dummy drug).

Overall, the drug extended patient survival from around 11 months to 14 months.

Side-effects were reported to be minor, and included nausea, occasional diarrhoea and a 'very small effect on the bone marrow.'

"Although it has never been rigorously compared with chemotherapy, from observing patients in the clinic it is clear that patients tolerate it much better than they do chemotherapy," Dr Parker said.

The researchers now intend to submit the findings for regulatory approval.

"I would hope that the authorities will approve radium-223 as a treatment for bone metastases in advanced prostate cancer soon," said Dr Parker.

"Additionally, the drug could be used in many other types of cancers which metastasise to bone, regardless of the primary site. We believe that our trial may have paved the way for improvements in survival for very many cancer patients."

http://uk.health.lifestyle.yahoo.net/prostate-cancer-drug-success-halts-trial.htm

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum